Los Angeles, July 22, 2022 (GLOBE NEWSWIRE) — Today, MDbio, in conjunction with their research partners at Radicle Science, are announcing the start of three separate clinical trial studies which will assess the efficacy of individual products that target sleeplessness, pain and stress. The purpose of the clinical trials is to understand the efficacy of three new plant-based MDbio products. During the trials, the doctors will test synergistic outcomes in multi-active formula compounds and determine the effects of drug holidays using plant-based medicines. MDbio will test their current lineup of products; MDsleep™, MDrelief™ and MDcalm™ on over 2,500 US adults. The trials will last 4 weeks, with the first trial beginning in August. All three products have already successfully gone through extensive internal observational trials, partially testing on patients from their own practices suffering from the corresponding condition.
“We are excited to team up with Dr. Chen and his colleagues in obtaining large scale efficacy trial data on our current portfolio of products. Their team embodies our commitment in developing prodicts that are derived from real scientific outcomes and working together with our patients and customers to always refine and better our product offering. Today continues our investment in developing medicines that are safe and effective.” said Brenden Dougherty, Chief Executive at MDbio.
The results from the highly anticipated…
